Spray-Dry Manufacture of Vaccine Formulations

October 1, 2013


Breit, J.F., and D.B. DuBose, “Spray-Dry Manufacture of Vaccine Formulations,” Bioprocess Int., 11:S9(2013)32-41.


Development of vaccines and immunotherapeutics has expanded rapidly due to technological advances in the fields of molecular biology and bioprocess engineering, as well as a smoothing of management and material logistics worldwide. Expression platforms and novel cell lines have enabled creation of increasingly complex vaccines. The advancement of vaccine formulation development is also capitalizing on new advances in manufacturing that use model-based methodologies gleaned from physiochemical principles, process analytical tools, and systematic approaches to problem solving. Herein we highlight recent advancements in spray-dried vaccine formulation, which has been successfully applied to develop stable and effective formulations across a spectrum of vaccine types.

Vaccine development has been incorporated into the era of biotechnology. The field of vaccines is as old as small-molecule therapeutics, with Jenner's smallpox vaccinations in 1796 and Withering's dosing of digitalis in 1785. Novel approaches to immunotherapies range from gene-based vaccines to protein subunits to protein complexes such as enveloped and nonenveloped virus-like particles and cell based therapies. As vaccines have increased in number and quality while varying in type, novel adjuvants have been advanced that focus on targeting specific cellular targets and immune responses.




Biotherapeutics / Bioprocessing